EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Jan. 29, 2008--SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today the addition of two new members on its board of directors. Robert C. Buhrmaster and Susan E. Knight have joined SurModics' board, bringing the current number of board members to nine.
Mr. Buhrmaster is the retired chairman, president and chief executive officer of Jostens, Inc., and also served in various roles at Corning, Inc., for 18 years. He also currently serves on the boards of The Toro Company and Innovex, Inc. He will become a member of the Audit Committee.
Ms. Knight is vice president and chief financial officer at MTS Systems, Inc., a leading global supplier of test systems and industrial position sensors, based in the Twin Cities. Prior to that Ms. Knight served in various management and executive positions with Honeywell International for 24 years. She also sits on the boards of Plato Learning and The Greater Metropolitan Housing Corporation. She will serve as a member of the Audit Committee.
"The board is quite pleased to have Bob and Sue join at this time, and we are gratified with the addition of two new directors who bring extensive experience to our board," commented Kendrick B. Melrose, chairman of the board. "We look forward to their contributions as SurModics' continues its growth."
About SurModics, Inc.
SurModics, Inc. is a leading provider of surface modification and drug delivery technologies to the healthcare industry. SurModics partners with the world's foremost medical device, pharmaceutical and life science companies to develop and commercialize innovative products that result in improved patient outcomes. Core offerings include: drug delivery technologies (coatings, microparticles, and implants); surface modification coating technologies that impart lubricity, prohealing, and biocompatibility capabilities; and components for in vitro diagnostic test kits and specialized surfaces for cell culture and microarrays. Collaborative efforts include a sustained drug delivery system in human trials for treatment of retinal disease and the drug delivery polymer matrix on the first-to-market drug-eluting coronary stent. SurModics is headquartered in Eden Prairie, Minnesota and its Brookwood Pharmaceuticals subsidiary is located in Birmingham, Alabama. For more information about the company, visit www.surmodics.com. The content of SurModics' website is not part of this release or part of any filings the company makes with the SEC.
Safe Harbor for Forward-Looking Statements
Certain statements contained in this press release may be deemed to be forward-looking statements under federal securities laws, and SurModics intends that such forward looking statements be subject to the safe harbor created thereby. SurModics does not undertake an obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT: SurModics, Inc.
Maggie Knack, Director, Investor Relations
SOURCE: SurModics, Inc.